With the goal of creating a clinically useful test to dichotomise wt KRAS mCRC patients with respect to Ctx sensitivity, Baker et al (2011) recently examined a set of 110 biologically based candidate gene expression biomarkers in primary tumour specimens from wt KRAS mCRC patients who had been treated with Ctx monotherapy. Here, KRAS is linked to neoplasm.